Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01925768 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 219
- Enrollment target
NCT01925768 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 219 participants.
The verdict
NCT01925768, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
Interventions
- DRUG Placebo
- DRUG Apremilast 30 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2013-09-04 |
| Est. Completion | 2016-11-17 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01925768
The ClinicalTrials.gov registry entry for NCT01925768 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01925768 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01925768 about?
NCT01925768 is a clinical study titled "Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis". The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.
What is the current status of trial NCT01925768?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 219 participants. The study started on 2013-09-04. Estimated completion is 2016-11-17.
What interventions are being tested in trial NCT01925768?
The interventions under investigation include: Placebo (DRUG), Apremilast 30 mg (DRUG).
Who is sponsoring clinical trial NCT01925768?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.